|display ongoing studies|
|Study||Ref.||Design||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results||new illness compatible with Covid-19 E||symptomatic Covid-19 E||conversion to SARS-CoV- 2–positive status via NP swab E|
COVID 19 outpatients meta-analysis
|RCT||peginterferon||placebo||COVID 19 outpatients||low||30/30||conclusif|
|1 study excluded by filtering options (1 RCT / 0 OBS)|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).